Golden
Stem Cell Theranostics

Stem Cell Theranostics

A biotechnology company founded in 2013 that develops technology to treat heart disease using pluripotent stem cells. Disease in a dish and clinical trial in a dish platforms are used to develop cardiovascular drugs and perform cardio-toxicity safety testing for non-cardiovascular drugs.

Stem Cell Theranostics is a biotechnology company using stem cells to treat cardiovascular diseases that is headquartered in Redwood City, California and was founded in 2013 by Anderw Lee. 



The company seeks to address patient-specific pathophysiology based on the patient’s genetic profile. The company has a relationship with Stanford Cardiovascular Institute with which they developed their discovery platform that can be used to develop genetically-targeted therapies while also addressing cardiotoxicity. 



Divya Nag and fellow student Andrew Lee started Stem Cell Theranostics with their professors. Nag is no longer with Stem Cell Theranostics, and has started StartX Med, a medical arm of Standford Student Enterprises Labs and now works for Apple in the Health Special Projects section. 

Funding

Series

On January 1, 2014 Stem Cell Theranostics completed their series A funding round with $5.5 million in funding from Bill Marcus. 

Timeline

People

Name
Role
LinkedIn

Joseph C. Wu M.D., Ph.D., FACC

Founder



Andrew Lee

Founder



Divya Nag

Founder



Robert C. Robb Jr.

Founder



Further reading

Title
Author
Link
Type
Date

Stem Cell Theranostics and Thermo Fisher Scientific Announce Collaboration to Advance Cardiomyopathy Disease Modeling Workflows

Stem Cell Theranostics Inc

Web



Stem Cell Theranostics secures "freedom to operate" in IP deal with GE Healthcare

Gareth Mcdonald

Web



Documentaries, videos and podcasts

Title
Date
Link

stem cell theranostics Archives - Stem Cell Podcast

August 18, 2015

Companies

Company
CEO
Location
Products/Services









References